'Different' GSK settles for $3 billion with US government
This article was originally published in Scrip
Executive Summary
GlaxoSmithKline says it has reached an agreement in principle with the US government to conclude its "most significant ongoing" federal investigations, investigations that GSK CEO Andrew Witty said " do not reflect the company that we are today." The cost of clearing up the legal messes amount to around $3 billion, not peanuts but less than the £2.9 billion ($4.6 billion) that the company had set aside for current legal provisions.